Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

References

• Cortes J, Hochhaus A, Hughes T, et al. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol. 2011;29(5):524–531.
   PubMed Web of Science ®Google Scholar
• Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857.
   PubMed Web of Science ®Google Scholar
• Hochhaus A. Educational session: managing chronic myeloid leukemia as a chronic disease. Hematology Am Soc Hematol Educ Program. 2011;2011(1):128–135.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Williams LA, Atallah E, et al. Chronic myeloid leukemia: what every practitioner needs to know in 2017. Am Soc Clin Oncol Educ Book. 2017;37:468–479.
   PubMedGoogle Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
   PubMed Web of Science ®Google Scholar
• Muffly LS, Hlubocky FJ, Khan N, et al. Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer. 2016;122(6):954–961.
   PubMed Web of Science ®Google Scholar
• Brochmann N, Flachs EM, Christensen AI, et al. Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clin Epidemiol. 2019;11:23–33.
   PubMed Web of Science ®Google Scholar
• Levin TT, Li Y, Riskind J, et al. Depression, anxiety and quality of life in a chronic lymphocytic leukemia cohort. Gen Hosp Psychiatry. 2007;29(3):251–256.
   PubMed Web of Science ®Google Scholar
• Gu M, Hao X, Cong L, et al. The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China. Medicine (Baltimore). 2019;98(50):e18196.
   PubMed Web of Science ®Google Scholar
• Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21(4):1097–1103.
   PubMed Web of Science ®Google Scholar
• Gauthier M, Conte C, Palmaro A, et al. Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population-based study in France. Fundam Clin Pharmacol. 2020;34(5):612–622.
   PubMed Web of Science ®Google Scholar
• Efficace F, Breccia M, Cottone F, et al. Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Support Care Cancer. 2016;24(12):4887–4894.
   PubMed Web of Science ®Google Scholar
• Ebrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc Sci Med. 1995;41(10):1383–1394.
   PubMed Web of Science ®Google Scholar
• Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference? Pharmacoeconomics. 2016;34(7):645–649.
   PubMed Web of Science ®Google Scholar
• Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003;21(11):2138–2146.
   PubMed Web of Science ®Google Scholar
• Jain P, Das VN, Ranjan A, et al. Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with imatinib or hydroxyurea. J Res Pharm Pract. 2013;2(4):156–161.
   PubMedGoogle Scholar
• Aziz Z, Iqbal J, Aaqib M, et al. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma. 2011;52(6):1017–1023.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118(17):4554–4560.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Wang H, Yu L, et al. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2017;143(12):2619–2630.
   PubMed Web of Science ®Google Scholar
• Guerin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014;30(11):2317–2328.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Wang HB, Yu L, et al. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. J Cancer Res Clin Oncol. 2017;143(6):1013–1022.
   PubMed Web of Science ®Google Scholar
• Ramsenthaler C, Gao W, Siegert RJ, et al. Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: a prospective, multi-centre longitudinal study. Palliat Med. 2019;33(5):541–551.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013;122(6):872–884.
   PubMed Web of Science ®Google Scholar
• Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971;12(6):371–379.
   PubMed Web of Science ®Google Scholar
• Zung WW. A Self-Rating Depression Scale. Arch Gen Psychiatry. 1965;12:63–70.
   PubMed Web of Science ®Google Scholar
• Leung K, Lue B, Lee M, et al. Screening of depression in patients with chronic medical diseases in a primary care setting. Fam Pract. 1998;15(1):67–75.
   PubMed Web of Science ®Google Scholar
• Liu XC, Oda S, Peng X, et al. Life events and anxiety in Chinese medical students. Soc Psychiatry Psychiatr Epidemiol. 1997;32(2):63–67.
   PubMed Web of Science ®Google Scholar
• Yu Y, Li M, Pu L, et al. Sleep was associated with depression and anxiety status during pregnancy: a prospective longitudinal study. Arch Womens Ment Health. 2017;20(5):695–701.
   PubMed Web of Science ®Google Scholar
• Li H, Jin D, Qiao F, et al. Relationship between the Self-Rating Anxiety Scale score and the success rate of 64-slice computed tomography coronary angiography. Int J Psychiatry Med. 2016;51(1):47–55.
   PubMed Web of Science ®Google Scholar
• Hao T, Youxiang M, Xiuyong D, et al. Prevalence and psychopathological characteristics of anxiety and depression in patients with chronic rhinosinusitis before endoscopic sinus surgery. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;50(3):210–214.
   PubMedGoogle Scholar
• Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249–4255.
   PubMed Web of Science ®Google Scholar
• Efficace F, Castagnetti F, Martino B, et al. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer. 2018;124(10):2228–2237.
   PubMed Web of Science ®Google Scholar
• Uyanik MS, Pamuk GE, Maden M, et al. The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients. Eur J Cancer Care. 2017;26(2):e12423.
   Web of Science ®Google Scholar
• Yu L, Huang X, Gale RP, et al. Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Medicine (Baltimore). 2019;98(48):e18079.
   PubMed Web of Science ®Google Scholar
• Sogawa R, Kimura S, Yakabe R, et al. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. Int J Clin Oncol. 2018;23(5):974–979.
   PubMed Web of Science ®Google Scholar
• Xu X, Shen B, Zhang A, et al. Anxiety and depression correlate with disease and quality-of-life parameters in Chinese patients with ankylosing spondylitis. Patient Prefer Adherence. 2016;10:879–885.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–224.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398–2406.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the Dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Yu L, Gale RP. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. J Cancer Res Clin Oncol. 2018;144(4):735–741.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Liu ZC, Zhang SX, et al. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2016;142(7):1539–1547.
   PubMed Web of Science ®Google Scholar
• Braamse AM, van Turenhout ST, Terhaar Sive Droste JS, et al. Factors associated with anxiety and depressive symptoms in colorectal cancer survivors. Eur J Gastroenterol Hepatol. 2016;28(7):831–835.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2014;23(3):825–836.
   PubMed Web of Science ®Google Scholar